ReviewCurrent opinion in infectious diseases2008
Tuberculosis in the developing world: recent advances in diagnosis with special consideration of extensively drug-resistant tuberculosis.
Review in Current opinion in infectious diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- A university-clustered tuberculosis outbreak during the COVID-19 pandemic in eastern China.Frontiers in public health · 2022Article
- Developments in the Diagnostic Techniques of Infectious Diseases: Rural and Urban Prospective.Advances in infectious diseases · 2018Article
- Current tuberculosis diagnostic tools & role of urease breath test.The Indian journal of medical research · 2012Review
- Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia.BMC infectious diseases · 2012Article
- Article
- Evaluation of tuberculosis diagnostics: establishing an evidence base around the public health impact.The Journal of infectious diseases · 2011Review
- Application of genotype MTBDRplus in rapid detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin in a high volume laboratory in Southern China.Molecular biology reports · 2011Article
- Article
- 13[C]-urea breath test as a novel point-of-care biomarker for tuberculosis treatment and diagnosis.PloS one · 2010Article
- Tuberculosis as part of the natural history of HIV infection in developing countries.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2010Review
- Diagnostic accuracy of the microscopic observation drug susceptibility assay: a pilot study from India.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2010Article
- Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis.Journal of clinical microbiology · 2010Article
- Point-of-care testing for disasters: needs assessment, strategic planning, and future design.Clinics in laboratory medicine · 2009Article
- Effect of efflux pump inhibitors on the susceptibility ofLung India : official organ of Indian Chest SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewGlobally tuberculosis is mainly diagnosed by sputum smear microscopy, which fails to detect half of all cases and fails to identify drug resistance. Inadequate global tuberculosis control through the directly observed therapy short course strategy alone and the growing threat of multidrug-resistant and extensively drug-resistant tuberculosis has driven recent development of new commercial and noncommercial tests, which are most desperately needed in resource-limited, high-burden settings. This review outlines the range of options currently available, highlighting particularly those recent developments with greatest potential for addressing the growing multidrug-resistant and extensively drug-resistant disaster as it affects those communities least technically and financially capable of controlling it. RECENT
findingsSimplification of molecular-diagnostic techniques, rapid-liquid culture and the use of colorimetric indicators have improved the sensitivity, speed and reliability of tuberculosis and multidrug-resistant tuberculosis detection, while decreasing cost and bringing diagnosis closer towards (though still some way from) the point-of-care. SUMMARY: Global tuberculosis control in 2008 demands the use of new tools for more sensitive and rapid detection of active disease and of drug resistance. Improved technologies are available for reference laboratories but for settings where resources and technical capacity are limited there is little ready for field implementation. The pipeline is promising, but in the interim wider use of liquid culture and manual or colorimetric drug susceptibility testing should be promoted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.